Silver Book Fact

Imatinib, the first chemical agent to target a cancer-specific protein, improved 5-year survival rates for chromosome-positive chronic myelogenous leukemia (CML) from 17% in the mid-1970s to 63% in 2007.

SEER Stat Fact Sheets: Chronic myeloid leukemia (CML). http://seer.cancer.gov/statfacts/html/cmyl.html. Accessed November 5, 2015

American Association for Cancer Research. AACR Cancer Progress Report 2015: Transforming lives through precision medicine. Clin Cancer Res. 2015; 21(S1). http://cancerprogressreport.org/Pages/default.aspx

Reference

Title
SEER Stat Fact Sheets: Chronic myeloid leukemia (CML)
Authors
Surveillance, Epidemiology, and End Results Program (SEER)
URL
Read Full Resource
Title
AACR Cancer Progress Report 2015: Transforming lives through precision medicine
Publication
Clin Cancer Res
Publication Date
2015
Authors
American Association for Cancer Research
Volume & Issue
Volume 21, Issue S1
Pages
S1-128
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Every additional dollar spent on overall breast cancer treatment has produced health gains valued at $4.80.  
  • The 1-year survival rate for lung cancer has increased from 37% in 1975 to 42% in 1999-2001, largely because of improvements to surgical techniques and with combined therapies.  
  • Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.  
  • Thousands of potential cancer medicines in development
     
  • Imatinib, the first chemical agent to target a cancer-specific protein, improved 5-year survival rates for chromosome-positive chronic myelogenous leukemia (CML) from 17% in the mid-1970s to 63% in 2007.